Low-osmolar Water Soluble Contrast Agent in Management of Adhesive Small Bowel Obstruction

Launched by QUEEN SAVANG VADHANA MEMORIAL HOSPITAL, THAILAND · Nov 14, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment approach for a condition called adhesive small bowel obstruction (ASBO), which can occur in people who have had abdominal surgery in the past. The trial aims to compare two different treatment methods: one using a special type of liquid called low-osmolar water-soluble contrast (Iohexol) and the other using traditional treatment methods. Researchers want to find out if using this contrast agent can help reduce the number of patients who need surgery for ASBO.

To participate in this study, individuals must be experiencing symptoms of small bowel obstruction due to adhesions and must have had abdominal surgery at least 30 days prior. However, people with certain serious conditions, such as signs of bowel strangulation or a history of allergic reactions to contrast agents, will not be eligible. While the trial is not yet recruiting participants, those who join can expect to receive either the new treatment or the standard care and help researchers learn more about the best ways to manage ASBO.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are presented with clinical manifestation of small bowel obstruction due to adhesion and require radiological investigations
• • Patients who has history of abdominal surgery over 30 days
• Exclusion Criteria:
• • Patients with clinical signs and symptoms of bowel strangulation, ischemia, perforation or peritonitis
• • Patients with clinical signs and symptoms of bowel obstruction from non-adhesive causes, including malignancy, herniation, inflammatory bowel disease, Crohn's disease, and others.
• • Patients who has history of allergy to water soluble contrast agent